| |
| |
 |
|
| |
| |
We're Firing Up the Competition—So You Can Build on Your Success |
|
| |
| |
If you didn't have the opportunity to win big in the first round of the Standard of Care Contest earlier this year, now is your chance to take part in round 2 of this exciting competition to ensure that GENVOYA, ODEFSEY, and DESCOVY remain the Standard of Care in HIV treatment. |
|
| |
| |
How the Contest Works |
|
| |
| |
The objective of this contest is to drive growth of regimens BUILT ON DESCOVY™ among a selected subset of target prescribers. Specifically, we will evaluate the growth of total regimens BUILT ON DESCOVY for your Top 15 TRIUMEQ writers within each territory's target list (Q3) and compare it with your baseline TRIUMEQ sales for your Top 15 TRIUMEQ writers. |
|
| |
| |
The national ranking by role (TS–HIV, TS–ADAP, OTS–HIV, OTS–ADAP, and RD) will be calculated for both percentage growth in GENVOYA + ODEFSEY + DESCOVY share and absolute growth in GENVOYA + ODEFSEY + DESCOVY share, over baseline, for 15 writers. Overall national ranking will be determined by averaging the rankings of both percent growth and absolute growth. Please keep in mind the Top 15 TRIUMEQ writers will be selected from your territory's target list and will be based on Total TRIUMEQ absolute volume bottles during the baseline period. |
|
| |
| |
Winners and Payout per Contest |
|
| |
| |
 |
|
| |
| |
Contest Schedule |
|
| |
| |
| Phase |
|
Baseline Period |
|
Measurement Period |
|
Expected Payout |
| 1 |
|
4/21/17-6/16/17 |
|
8/21/17-10/20/17 |
|
December 2017 |
| 2 |
|
6/23/17-8/18/17 |
|
10/23/17-12/22/17 |
|
February 2018 |
|
|
| |
| |
LEAD THE WAY BY MAKING REGIMENS
BUILT ON DESCOVY (FTC/TAF)
THE STANDARD OF CARE FOR HIV! |
|
| |
| |
Sincerely, |
|
| |
| |
Dave Alex – SRD, HIV Central
John Hilton – SRD, HIV West
Jamie Jones – SRD, HIV East |
|
| |
| |
| |
ELIGIBILITY RULES |
|
| |
| |
| • |
All eligible TSs, OTSs, and RDs can participate in the contest
|
| |
| |
| - |
Eligibility will be determined for each 9-week "Phase Period"
|
|
| |
| • |
Must be 100% "IC Eligible" during each phase measurement period to be eligible to participate in a specific phase |
| |
| • |
Must not be on Unpaid Leave of Absence during each phase measurement period to be eligible to participate in a specific phase
|
| |
| • |
Must not have a written warning on file during contest period |
| |
| • |
New hires attending September 2017 classes will be qualified for Phase 2 only |
| |
| • |
Must be employed by Gilead at the time of payout |
|
|
| |
| |
ADDITIONAL ELIGIBILITY RULES |
|
| |
VACANT TERRITORIES |
|
| |
| • |
In the event that a vacant territory/region is a contest winner, the next highest-ranked territory/region will replace the vacant territory/region as a winner
|
|
|
| |
| |
TIES IN OVERALL RANKING |
|
| |
| • |
If there is a tie between 2 or more participants for the final award spot, the tie will be broken by giving the award to the participant who had the highest (GEN+ODE+DVY)/NRTI Share "absolute growth"
|
| |
| • |
Share values will be truncated for display purposes but unrounded for actual calculations
|
| |
| • |
Baselines may change based on data restatements
|
|
|
| |
| |
| |
|
|
| |
| |
© 2017 Gilead Sciences, Inc. All rights reserved. 8/17 |
|
| |
| |
THIS DOCUMENT IS FOR INTERNAL USE ONLY. GILEAD CONFIDENTIAL. |
|
| |
